Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Aileen L Pangan"'
Autor:
Joseph F Merola, Frank Behrens, Marina Magrey, Liang Chen, Derek Haaland, Koji Kato, Mitsumasa Kishimoto, Patrick Zueger, Aileen L Pangan, Cesar Pacheco-Tena, John Liu, Yuanyuan Duan, Ralph Lippe
Publikováno v:
RMD Open, Vol 7, Iss 3 (2021)
Externí odkaz:
https://doaj.org/article/3246209a50e946a796e8247c73843f2e
Autor:
Désirée van der Heijde, Joachim Sieper, Walter P. Maksymowych, Robert G. Lambert, Su Chen, Maja Hojnik, Jaclyn K. Anderson, Aileen L. Pangan
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-13 (2018)
Abstract Background Adalimumab was effective in treating patients with nonradiographic axial spondyloarthritis (nr-axSpA) in the 12-week ABILITY-1 trial. We present long-term efficacy and safety results of adalimumab from the open-label ABILITY-1 ext
Externí odkaz:
https://doaj.org/article/38a09d984ba445db80056c5594275dae
Autor:
Atul Deodhar, Filip Van den Bosch, Denis Poddubnyy, Walter P Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Ricardo Blanco, Yuanyuan Duan, Yihan Li, Aileen L Pangan, Peter Wung, In-Ho Song
Publikováno v:
The Lancet. 400:369-379
Upadacitinib, a Janus kinase inhibitor, has been shown to be effective in patients with ankylosing spondylitis. We aimed to assess the efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis.The SELECT-AXIS 2 non-radiographic
Autor:
Silvio Danese, Séverine Vermeire, Wen Zhou, Aileen L Pangan, Jesse Siffledeen, Susan Greenbloom, Xavier Hébuterne, Geert D'Haens, Hiroshi Nakase, Julian Panés, Peter D R Higgins, Pascal Juillerat, James O Lindsay, Edward V Loftus, William J Sandborn, Walter Reinisch, Min-Hu Chen, Yuri Sanchez Gonzalez, Bidan Huang, Wangang Xie, John Liu, Michael A Weinreich, Remo Panaccione
Publikováno v:
The Lancet, 399(10341), 2113-2128. Elsevier Limited
BACKGROUND There is a great unmet need for advanced therapies that provide rapid, robust, and sustained disease control for patients with ulcerative colitis. We assessed the efficacy and safety of upadacitinib, an oral selective Janus kinase 1 inhibi
Autor:
Sofia Ramiro, Philip J. Mease, Xin Wang, Laura C Coates, In-Ho Song, William Tillett, Tianshuang Wu, Aileen L. Pangan, Sonya Abraham
Publikováno v:
Arthritis Care & Research. 74:259-267
OBJECTIVES To examine concurrent validity and discrimination of modified minimal disease activity (mMDA) criteria in peripheral spondyloarthritis (pSpA) following OMERACT filter principles and determine predictors of mMDA response. METHODS Four mMDA
Autor:
P. Zueger, William Tillett, A. Lertratanakul, R. Mccaskill, Aileen L. Pangan, Philip J. Mease, Xianwei Bu, Liang Chen, M. Keiserman, Filip Van den Bosch, Kim A. Papp, E. Mcdearmon-Blondell, S. Tsuji, Eva Dokoupilova
Publikováno v:
Rheumatology and Therapy
RHEUMATOLOGY AND THERAPY
RHEUMATOLOGY AND THERAPY
Introduction Upadacitinib is a Janus kinase inhibitor under investigation in patients with psoriatic arthritis (PsA). This study assessed the 56-week efficacy and safety of upadacitinib in patients with PsA and an inadequate response or intolerance t
Autor:
Joseph F. Merola, Jaclyn K Anderson, Marina Magrey, Liang Chen, P. Zueger, César Pacheco-Tena, J. Liu, Iain B. McInnes, X. Wang, Mitsumasa Kishimoto, Yi Liu, Frank Behrens, Aileen L. Pangan, Slawomir Jeka
Publikováno v:
New England Journal of Medicine. 384:1227-1239
Background The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor a inhibitor, in patients who have an inadequate response
Autor:
Maureen Rischmueller, Naomi Martin, N. Khan, Aileen L. Pangan, Ying Zhang, Jeffrey Enejosa, Boulos Haraoui, Ricardo Machado Xavier, A. Rubbert-Roth
Publikováno v:
New England Journal of Medicine. 383:1511-1521
Background Upadacitinib is an oral selective Janus kinase inhibitor to treat rheumatoid arthritis. The efficacy and safety of upadacitinib as compared with abatacept, a T-cell costimulatio...
Autor:
Ronald F van Vollenhoven, Aileen L. Pangan, Tsutomu Takeuchi, Ricardo Blanco, Vibeke Strand, Maureen Rischmueller, Su Chen, Mohamed-Eslam F. Mohamed, Ricardo Machado Xavier, Alan Friedman
Publikováno v:
Repositório Institucional da UFRGS
Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
Arthritis & Rheumatology (Hoboken, N.j.)
van Vollenhoven, R, Takeuchi, T, Pangan, A L, Friedman, A, Mohamed, M E F, Chen, S, Rischmueller, M, Blanco, R, Xavier, R M & Strand, V 2020, ' Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY) : A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator–Controlled Trial ', Arthritis and Rheumatology, vol. 72, no. 10, pp. 1607-1620 . https://doi.org/10.1002/art.41384
Arthritis and Rheumatology, 72(10), 1607-1620. John Wiley and Sons Ltd
Arthritis & rheumatology (Hoboken, N.J.), 72(10), 1607-1620. John Wiley and Sons Ltd
Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
Arthritis & Rheumatology (Hoboken, N.j.)
van Vollenhoven, R, Takeuchi, T, Pangan, A L, Friedman, A, Mohamed, M E F, Chen, S, Rischmueller, M, Blanco, R, Xavier, R M & Strand, V 2020, ' Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY) : A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator–Controlled Trial ', Arthritis and Rheumatology, vol. 72, no. 10, pp. 1607-1620 . https://doi.org/10.1002/art.41384
Arthritis and Rheumatology, 72(10), 1607-1620. John Wiley and Sons Ltd
Arthritis & rheumatology (Hoboken, N.J.), 72(10), 1607-1620. John Wiley and Sons Ltd
Objective: The SELECT-EARLY trial was undertaken to study the effect of upadacitinib, an oral, reversible Janus kinase 1–selective inhibitor, as monotherapy in patients with predominantly early rheumatoid arthritis who were naive for or had limited
Autor:
Wen Zhou, M A Weinreich, Silvio Danese, Severine Vermeire, Aileen L. Pangan, Hiroshi Nakase, R Pannaccione, Peter D.R. Higgins, Bidan Huang, Xavier Hébuterne, Y Sanchez-Gonzalez, M H Chen, Wangang Xie, Jesse S. Siffledeen, J Liu
Publikováno v:
Journal of Crohn's & Colitis
Background An unmet therapeutic need remains in patients with ulcerative colitis (UC). U-ACHIEVE is one of two phase 3 induction trials evaluating the safety and efficacy of the selective Janus kinase–1 inhibitor upadacitinib (UPA) 45 mg once daily